Report Overview

The Europe Migraine Drugs market size stood at around USD 1.17 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Migraine is a neurological condition, which most frequently manifests as severe, recurrent headache. It may be accompanied with other symptoms like visual disturbances, nausea, aura and more. It shows a female predilection. It is the third most and prevalent and the sixth most disabling disease in the world.

In Netherlands, the number of migraine cases rose sharply from 1991 to 2014. Since then, the number of incident cases has remained almost constant.

The health care expenditure for migraine was 37.4 million euros in 2017 in Netherlands. This corresponds to 0.64% of the total health care expenditure for diseases of the nervous system and senses and 0.04% of the total health care expenditure in the Netherlands. Most of the care expenditure for migraine was spent on medicines and aids (69%), followed by primary care (19%).



 

Market Drivers

Migraine has a high prevalence rate, specifically in females of the age group 44 to 55 years. In 2019, Netherlands had 279,000 cases of migraine, out of which 219,000 were women and 60,200 were men. This corresponds to 7.0 per 1,000 men and 25.2 per 1,000 women. The market is expected to be driven by the increasing proportions of female and aging population.

Another market driver is increased awareness and increasing expenditure on healthcare needs. Increasing stress levels, which is a risk factor, will also drive the market.

There is also a focus on research and development of migraine drugs. Six drugs are in late stage clinical process and three novel drugs are in the pipeline.